Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether genetic factors contribute to an individuals risk of developing obstructive lung disease from smoking cigarettes.


Clinical Trial Description

Chronic obstructive pulmonary disease (COPD) is among the most important chronic diseases of adults. It is the fourth leading cause of death in the U.S. and affects more than 10% of the U.S. population over age 55. COPD accounts for more than 25,000 discharges annually from VA medical centers. Cigarette smoking is the most important known modifiable cause of COPD, yet only 15-20% of cigarette smokers develop clinically significant COPD. We therefore hypothesize that genetic mechanisms determine susceptibility to the development of COPD. The only genetic abnormality known to cause COPD is deficiency of the serine protease inhibitor 1-protease inhibitor, which causes premature development of emphysema, although it is implicated in fewer than 2% of COPD cases. Several other genetic variants have been proposed as candidate causes of COPD; however, these have been identified on the basis of association studies in unrelated subjects, which have considerable risk of ascertainment bias. In the present study, a sub-pair linkage approach will be utilized in COPD patients and their smoking siblings to identify genes which determine the risk of developing COPD. The following are the short-term objectives of this study:

1. Recruit a cohort of 400 probands with smoking-related COPD and their smoking siblings, whether or not affected by COPD. Affected subjects will be extensively characterized as to specific COPD phenotype, using spirometry, computed tomography, and questionnaire data.

2. Test the association of known genetic variants in candidate genes to the presence of COPD.

3. For proposed candidate genes without known candidate polymorphisms, use sib-pair linkage analysis to test polymorphic marker loci in close proximity to the candidate gene for evidence of linkage to COPD.

4. Test for heterogeneity of linkage among different COPD phenotypes: predominant emphysema versus predominant airway disease.

The long-term objective of this research is the identification of specific genetic variants which confer risk for the development of COPD in smokers. This will be achieved by means of fine mapping of the loci identified in objectives 3-4 above, or in a subsequent genome scan involving the 400 sibling pairs; identification of novel genetic variants at these loci; and assessment of the functional significance of these variants and their relation to COPD in an independent sample of subjects.

Recruitment of subjects for this project began in April, 1999. At this time, a total of 22 subjects (11 COPD patients and 11 first-degree relatives) have been recruited and tested. No adverse events have occurred. A computerized methodology for quantitation of emphysema from CT scans has been developed and has demonstrated adequate DNA extraction from our blood samples. Genotyping has been deferred pending the recruitment of 50 subjects. ;


Study Design

Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT00018408
Study type Observational
Source VA Office of Research and Development
Contact
Status Completed
Phase N/A
Start date October 1998
Completion date September 2001

See also
  Status Clinical Trial Phase
Withdrawn NCT01416701 - Vitamin D and Chronic Obstructive Lung Disease Phase 4
Completed NCT01362855 - Advance Care Planning Evaluation in Hospitalized Elderly Patients
Completed NCT00202150 - Primary Care Management/Action Plans for Advanced Chronic Diseases Phase 2/Phase 3
Recruiting NCT05227547 - Mapping and Characterization of Alveolar Cells During Smoking and Chronic Obstructive Disease N/A
Withdrawn NCT02273349 - Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency N/A
Completed NCT02987439 - COPD-EXA-REHAB. Early Pulmonary Rehabilitation of Patients With Acute Exacerbation of COPD N/A
Completed NCT01950936 - Procalcitonin To Reduce Antibiotics in Chronic Obstructive Lung Disease (ProToCOLD) Phase 2/Phase 3
Completed NCT01404000 - Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal Phase 2
Terminated NCT03811158 - The Edi Level and Cardiopulmonary Function Between HHHFNC and Unheated Humidified High-Flow Oxygen Mask in COPD N/A
Recruiting NCT01631162 - The Identification of Different Lung Diseases by Analysis of Volatile Organic Compounds in Breath Samples N/A
Completed NCT01596023 - Evaluation of Breathe NIOV System on Work of Breathing in Chronic Obstructive Lung Disease Patients N/A
Completed NCT01347931 - In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency N/A
Terminated NCT01712854 - Effects of Symbicort on the Ventilatory Kinematics Phase 4
Completed NCT02462343 - Comparison of the Two and Six- Minute Walk Tests in Evaluating Oxygen Desaturation in Patients With Severe COPD N/A
Recruiting NCT06090149 - Telemedical Assistance in Automatic Titration of Oxygen for Intensive Care Patients N/A
Recruiting NCT02778802 - Pulmonary Hemodynamics in Patients With Severe Emphysema Pre and Post BLVR N/A
Enrolling by invitation NCT02278107 - Evaluation of a Lightweight Nasal Interface and Ventilator in Patients With Respiratory Disease N/A
Completed NCT01614951 - The Pulmonary Protection Trial Phase 4
Completed NCT01787097 - Effect of Symbicort ® on GR in Sputum in COPD Phase 4
Completed NCT01495780 - eRT Remote Health Monitoring N/A